Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting

Background: Up to 10% of patients with advanced non-small cell lung cancer (aNSCLC) have pre-existing interstitial lung disease (ILD). These patients are usually excluded from immunotherapy clinical trials. Consequently, knowledge on outcomes following nivolumab treatment in these patients remains l...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic advances in medical oncology 2023-01, Vol.15, p.17588359231152847
Main Authors: Assié, Jean-Baptiste, Chouaïd, Christos, Nunes, Hilario, Reynaud, Dorothée, Gaudin, Anne-Françoise, Grumberg, Valentine, Jolivel, Ronan, Jouaneton, Baptiste, Cotté, François-Emery, Duchemann, Boris
Format: Article
Language:English
Subjects:
Cancer
Clinical trials
Comorbidity
Immunotherapy
Life Sciences
Lung cancer
Lung diseases
Monoclonal antibodies
Non-small cell lung carcinoma
Original Research
Patients
Santé publique et épidémiologie
Small cell lung carcinoma
Survival analysis
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Up to 10% of patients with advanced non-small cell lung cancer (aNSCLC) have pre-existing interstitial lung disease (ILD). These patients are usually excluded from immunotherapy clinical trials. Consequently, knowledge on outcomes following nivolumab treatment in these patients remains limited. The primary objective of this study was to evaluate survival outcome following nivolumab treatment in ILD patients with pre-treated aNSCLC in the real-world setting. Patients and methods: The study included all patients with aNSCLC recorded in the French hospital database, starting nivolumab in 2015–2016. Patients were stratified by pre-existing ILD and three subgroups were studied [auto-immune or granulomatous (AI/G) ILD, other known causes ILD and idiopathic ILD]. Time to discontinuation of nivolumab treatment [time to treatment duration (TTD)] and overall survival (OS) were estimated using Kaplan–Meier survival analysis. Results: Of 10,452 aNSCLC patients initiating nivolumab, 148 (1.4%) had pre-existing ILD. Mean age at nivolumab initiation was 64.6 ± 9.4 years in ILD and 63.8 ± 9.6 years in non-ILD. Compared to non-ILD, patients in the ILD group were more frequently men (p 
ISSN:1758-8359
1758-8340
1758-8359
DOI:10.1177/17588359231152847